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Abstract
Analysis of donor chimerism has become a routine
method for the documentation of engraftment after allo-
geneic hematopoietic stem cell transplantation (HSCT).
In recent years several groups have also focused on the
application of this technique for the detection of relaps-
ing disease after allogeneic HSCT. This review addresses
technical issues (sensitivity, specificity) and discusses
the advantages and limitations of methods currently
used for chimerism analysis and their usefulness for the
detection of MRD. In addition, the potential impact of
novel procedures, e.g. subset chimerism or real-time
PCR-based procedures, is discussed.
Copyright © 2004 S. Karger AG, Basel
Introduction
After allogeneic blood stem cell transplantation, a
coexistence of the host and donor lympho- and hemato-
poietic system will develop. This period, which is tempo-
rary in the majority of successful stem cell transplants, is
referred to as mixed chimerism, whereas complete chi-
merism denotes the situation, when all cell lineages are
reconstituted by the donor. The evaluation of chimerism
after stem cell transplantation has been of central inter-
est since this treatment has been used clinically. Several
techniques have been applied for this purpose during the
last 30 years, including cytogenetics, isoenzyme analysis
and blood group phenotyping [for a review, see 1]. A
major improvement in the clinical applicability was
made when differentiation of sex chromosomes using
fluorescence in situ hybridization (FISH) became possi-
ble [2, 3]. This method allows rapid and quantitative
evaluation of engraftment; however, it is obviously re-
stricted to the approximately 50% of patients trans-
planted from a sex-mismatched donor. The invention of
the polymerase chain reaction (PCR) was a key step
which laid the fundament for the development of mod-
ern molecular diagnostics [4]. In the field of chimerism
diagnostics, several PCR-based procedures have been de-
veloped for the evaluation of engraftment [5–16]. Most
of these assays rely on the amplification of highly poly-
morphic repetitive DNA sequences, i.e. short tandem
repeats (STR) or a variable number of tandem repeat
(VNTR) sequences.
Besides the documentation of engraftment, detection
of reappearing leukemic cells has become a key issue in
chimerism diagnostics. Numerous publications deal with
this application. This review focuses on the use of chime-
rism analysis for the detection of minimal residual leuke-
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Table 1. Comparison of different methods for chimerism analysis
Method Sensitivity1, % Advantages Disadvantages Ref.
XY-FISH 0.1 Quantitative relatively sensitive,
fast, standardized technique
Restricted to sex mismatch 2, 3
Real-time PCR 0.1–0.0001 Quantitative, highly sensitive False positive results possible in
SNP-based procedures 
23–25
Red cell phenotyping Fast sensitive Long latency makes it unsuitable for
rapidly proliferating diseases
26
STR or VNTR-PCR 5–1 Informative, low amounts of
material, rapid
Moderate sensitivity 5–16
YX-FISH and immuno-
histochemistry (FICTION)
0.1–0.001 Sensitive, cell line specific Labour intensive, restricted to sex
mismatch
27–30
STR-PCR + cell sorting 0.1–0.0001 Sensitive, cell line specific Labor intensive, requires specific
equipment
31–34
* The lower level of host cells detectable is denoted.
mia and addresses several questions which may be impor-
tant in this context: (1) Are the current methodologies for
chimerism analysis appropriate for the detection of mini-
mal residual disease (MRD)? (2) If so how can they poten-
tially be further improved? (3) If not, which alternatives
can be found to sufficiently solve the problem?
Methods for Chimerism Analysis and Their
Sensitivity
The first of these questions is especially important. The
term MRD describes a state of leukemic burden which is
below the threshold detection level of conventional mea-
sures, i.e. morphology. This standard method for assess-
ment of response towards chemotherapy has, by defini-
tion, a limit of detection for leukemic blasts in the bone
marrow of 5% [17]. Thus any procedure which can mea-
sure cells below this level may be suitable to detect leu-
kemic cells. But what level of sensitivity should we
approach? Generally one might wish to know precisely
which level of MRD has been reached. Thus, it is much
more important to quantitatively assess the level of resid-
ual leukemia than to deal with merely qualitative analy-
ses. The level of detection achievable can be illustrated by
comparing several techniques which are currently used
for the detection of residual leukemia after treatment. For
example, FISH detection of chromosomal translocations
has a level of sensitivity between 0.1 and 8% depending
on the technique used and the specific translocation
investigated [recent review in 18]. Flow-cytometric as-
says, monitoring aberrant antigen expression, might
achieve considerably higher levels of sensitivity, between
0.01 and 1% [recent examples in 19, 20]. PCR, however,
represents the most sensitive technique reported so far.
The exponential amplification of specific target sequences
facilitates a limit of detection between 0.1 and 0.01%
cells. This sensitivity can be further increased if two con-
secutive rounds of PCR are applied, which routinely
detects 1/105 to 1/106 cells, and which can be further
increased and has been used even to demonstrate the
presence of leukemia-associated translocations in healthy
individuals [21]. The diagnostic message can be substan-
tially augmented when quantitative PCR methods (real-
time PCR) are applied, which gives information on the
number of starting molecules [22]. Thus, taken together
there is a broad range of methods for the detection of
residual leukemia. The methods currently in use for chi-
merism analysis must be interpreted in this context, if dis-
cussing their value in the detection of MRD. Table 1 sum-
marizes different techniques for chimerism analysis, their
advantages and disadvantages as well as the reported lev-
els of sensitivity.
Among these assays, STR-based methods are the most
frequently used. These methods usually have a level of
sensitivity between 1 and 5%, a range which allows the
accurate and reliable monitoring of engraftment. In addi-
tion, there is evidence that at least in slowly proliferating
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diseases like CML, this level may be sufficient for the rou-
tine follow-up. Several reports have shown that increasing
mixed chimerism is a sensitive predictor of relapse in
cases with persistent positivity for the bcr-abl fusion
transcript [35, 36]. However, these data mainly originate
from the era before real-time PCR for the bcr-abl mRNA
has become widely available [37]. Today, the quantitative
information on the bcr-abl copy numbers is regarded as
the most important diagnostic tool in this disease [for a
review, see 38]. Nevertheless, chimerism analysis may be
an important adjunct method to assess the response
towards donor leukocyte infusion (DLI) [30, 32]. In addi-
tion, analysis of chimerism in bone marrow CD34+ cell
before DLI may give valuable information on the risk of
developing aplasia after DLI [39]. Chimerism analysis in
transplant settings using T cell depletion to schedule T cell
add-back and to monitor the success of this intervention
may also be of special importance, especially in trans-
plants with dose-reduced conditioning [40].
Conflicting data have been reported on the question of
whether standard STR-based procedures are also useful
for the early detection of reappearing disease in acute leu-
kemias. There are several reports indicating that a level of
about 1% may be sufficient to detect relapse in acute leu-
kemia. Bader et al. [41] described the use of overall chi-
merism analysis in 30 transplanted children with acute
lymphoblastic leukemia (ALL), acute myeloid leukemia
(AML) and MDS. Patients who showed mixed chimerism
had a significantly higher probability of relapse compared
to those with stable complete chimerism. However, there
were also patients within this cohort who had increasing
host chimerism without relapse as well as 3 patients who
had complete chimerism before relapse. A later analysis
by the same group of 55 patients confirmed these data
[42]. Similar data, indicating that chimerism analysis
from unsorted peripheral blood or bone marrow samples
is able to detect relapse, were published by several groups
[43, 44]. In contrast, other groups were not able to demon-
strate a good prediction of relapse by analyzing chimerism
from the peripheral blood. Suttorp et al. [9] showed that
an RFLP assay with a 1% sensitivity showed complete
chimerism 30–86 days before a clinical relapse was diag-
nosed. They concluded that the kinetics of reappearing
leukemia are too rapid to be diagnosed with a detection
limit of 1%. Comparable results were seen by other groups
[45–48]. Taking these results together, mixed chimerism
may precede subsequent relapse, but the interval between
the decrease in donor cells using STR or VNTR-PCR and
the clinical diagnosis is much too short to make meaning-
ful clinical decisions in the majority of the patients. The
background of these discrepancies in the reports on the
usefulness of chimerism analysis of peripheral blood is
not yet clear. The reasons may be technical (e.g. different
levels of sensitivity) or different sampling protocols. They
may also be related to different patient populations, since
the majority of data showing sufficient sensitivity are
from pediatric transplantations. However, an increase in
sensitivity is clearly desirable to improve the detection
range of residual host cells and to potentially increase the
time for clinical decision making.
New Techniques for the Detection of MRD
Using Chimerism Analysis
As stated above, STR-based methods have a level of
sensitivity which is in the range of 1–5%. One additional
problem associated with this technique is the diagnostic
uncertainty induced by PCR artifacts (stutter signals)
[49], which renders a large number of peak constellations
insufficient for analysis, because a residual host signal is
located within the stutter peak of the donor, and thus can-
not be detected accurately [50]. To overcome this limita-
tion, a selection of STRs with a high proportion of donor/
recipient constellations without interference of host and
donor signals is desirable. In a recent analysis of 27 differ-
ent STRs in a population of 203 HLA-matched related
donors and recipients, we have identified a subset of
markers with a high likelihood of finding such constella-
tions [50a]. However, even if STR-based assays for chi-
merism analysis may be further improved and may detect
leukemic cells in some patients, according to our experi-
ence and most of the published data the detection is too
late in most of the patients to facilitate early intervention,
e.g. tapering of immunosuppressive therapy. Thus in
order to detect recurring disease as early as possible, novel
assays with higher sensitivity would be a major improve-
ment. Recently, quantitative chimerism analysis using
real-time PCR has been reported for this purpose. Real-
time PCR, either by the 5)-nuclease assay (TaqMan proce-
dure) or by fluorescent resonance energy transfer, has the
advantage that the product yield of the PCR is measured
during each cycle, which allows the calculation of the
number of starting molecules [for a review, see 22]. Real-
time PCR monitoring has become a standard procedure
for the evaluation of the response to therapy in acute and
chronic leukemias and has been shown to be a sensitive
and predictive tool for the guidance of treatment. It relies
on the amplification of a specific target sequence, such
as fusion oncogenes (e.g. bcr-abl, PML-RARalpha) or B or
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T cell receptor rearrangements [22]. However, in a large
proportion of acute leukemias, such specific molecular
targets are missing. In male patients transplanted from a
female donor, the Y chromosome represents a unique
characteristic of recipient cells. Lo et al. [51] were the first
to use real-time PCR for the SRY gene on the Y chromo-
some to detect microchimerism due to fetomaternal
transfer in females who have given birth to male children.
Fehse et al. [23] have reported a similar method for the
evaluation of chimerism after hematopoietic stem cell
transplantation (HSCT). However, clinical data on the
use of this procedure are still missing. We used real-time
PCR for the SRY gene on the Y chromosome to quantify
the level of chimerism in 43 male patients transplanted
from a female donor [52]. This method was shown to have
a lower limit of detection of one male cell in 100,000
female cells. Our results indicate that residual host cells
are detectable at very low levels in almost all patients
investigated up to 5 years after transplantation. In addi-
tion, a gradual decrease of residual host cells was found
over time (median 1 month: 0.3%; median 6 months:
0.01%; median 1 year: 0.0061%; median 4 years:
0.0015%). This persistence of host cells over long periods
at low levels might explain why earlier reports using end
point PCR did not show any impact of the detection of
residual host cells [53]. In contrast, using real-time PCR,
patients with relapse showed an increase in the percentage
of host cells which preceded the haematological relapse by
up to 120 days. Thus, real-time PCR might represent an
interesting tool to analyze the level of residual host cells.
As discussed earlier, the Y chromosome can be used only
in a subset of patients. Several groups have now reported
real-time PCR assays using other genetic targets, i.e. sin-
gle nucleotide polymorphisms (SNPs), for the differential
amplification of host cells after transplantation. SNPs are
mostly biallelic genetic variances which occur on average
every 1,000 bp, thus about 3,000,000 of these polymor-
phisms are present. Alizadeh et al. [54] recently published
a set of 11 biallelic SNPs for real-time PCR analysis after
allogeneic HSCT. These SNPs could discriminate 90% of
the donor and recipient constellations tested. The assay
has a minimum sensitivity of 0.1%, which is not as sensi-
tive as for the SRY gene, but at least 10-fold better than
for standard STR or VNTR-based methods. Maas et al.
[25] also published data on the use of real-time PCR for
chimerism analysis with very similar results. In summary,
real-time PCR-based procedures will provide an impor-
tant improvement of the diagnostic inventory for chimer-
ism analysis. However, as shown by several authors, real-
time PCR cannot totally replace STR- or VNTR-based
methods. One substantial drawback of this technique is
the lower quantitative accuracy [25, 54]. This problem is
inherent in the technique, since a change of only one PCR
cycle means a 2-fold quantitative difference. This implies
that a coefficient of variation of about 20–30% must be
considered as normal. In contrast, STR-based procedures,
especially when performed in a multiplex PCR, achieve
reproducibility values between 4 and 8% [50, 55]. Thus in
states of chimerism exceeding 5% host signal, STR analy-
sis remains the method of choice. This technique is also
superior to real time in the analysis of subset populations
due to the limitations discussed above.
Another possibility to increase the sensitivity of a chi-
merism analysis is the use of specific subpopulations of
the peripheral blood or bone marrow. The enrichment of
cellular compartments has been shown to increase the
sensitivity of chimerism analysis, since specific popula-
tions of cells, like B cells, T cells or early stem cells, are
enriched from the background of mature granulocytes.
Ginsburg and coworkers [56] were the first who described
the investigation of cellular subsets after HSCT; van
Leeuwen et al. [57] were the first to use highly purified
cellular populations. Meanwhile, several groups have re-
ported the analysis of chimerism in specific subsets to
detect reappearing leukemic cells [27, 34, 58–61] or to
monitor the effect of treatment [30].
Lamb et al. [58] described the use of subset analysis to
differentiate suspicious relapse in two cases. In one pa-
tient they did not find evidence for relapse, whereas the
second patient showed relapse in the CD34+/CD7+ leu-
kemic cells, which was undetectable in the unsorted bone
marrow material. Zetterquist et al. [60] compared chimer-
ism analysis in sorted B cells with overall chimerism and
PCR for clone specific T cell or B cell receptor rearrange-
ments. Mixed chimerism in the B cell compartment was
found in 5 patients who also showed persistence of the
clonality marker in the PCR. Mixed chimerism in the B
cells was detected 2.5 months prior to the morphological
relapse in 3/4 patients with relapse. No relapse was
observed in those seven cases with complete donor chi-
merism in the B cell compartment. Mattson et al. [34]
studied 30 patients with AML and MDS. They used
immunomagnetic labeling with antibodies against CD33,
CD7 or CD45 to enrich the specific subpopulations from
the peripheral blood or the bone marrow, achieving a final
sensitivity between 2 and 4 ! 10–4. Mixed chimerism in
these populations 1 month after transplantation was ob-
served in 14 of the 30 patients. A relapse was seen in 10/
14 patients with mixed chimerism in the subpopulations
compared to only 2/16 cases with complete chimerism, a
20 Acta Haematol 2004;112:16–23 Thiede/Bornhäuser/Ehninger
difference which was highly significant. Interestingly,
mixed chimerism in the peripheral blood seemed to have
a lower sensitivity (67%), but a higher specificity (100%)
in the prediction of relapse compared to the analysis of
bone marrow samples.
We have recently performed a study using CD34+ cells
as target for the identification of leukemic cells. The basic
idea behind this was that the CD34 antigen is expressed
on a very small population of normal hematopoietic pro-
genitor cells, but can be frequently detected on blasts of
different leukemias [62, 63]. Evaluation of this method
showed a minimum sensitivity of 1/40,000 cells [33]. In a
panel of 87 prospectively investigated patients, chimer-
ism analysis in the CD34+ cells was performed for the
detection of relapse [61]. After a median follow-up of 295
days (range 28–1,152 days), a total of 22 relapses were
observed in the 84 patients showing engraftment. Relapse
was associated with a decrease in CD34+ cell donor chi-
merism by up to 97 days in 20/22 patients. In patients
with CML and molecular relapse, recurrent disease was
associated with a decrease in donor CD34+ cells. Treat-
ment with DLI or imatinib resulted in an increase in
donor CD34+ cells and a clearance of bcr-abl-positive
cells. Since this assay can be performed with peripheral
blood, the investigations can be done at short intervals.
These data inspired us to start a randomized prospective
multicenter trial comparing chimerism from the peripher-
al blood and subset chimerism within the CD34 compart-
ment in patients with AML, ALL or MDS whose leuke-
mia blasts express the CD34 antigen. In patients showing
a decrease in the proportion of donor CD34+ cells below
60%, immunosuppression is reduced or DLIs are given.
First results of this study are inspiring and we have seen
responses in several cases of AML and ALL.
Thus taken together, these data clearly show that sub-
set analysis is a very sensitive technique, with a limit of
detection comparable to nested PCR. This technique
adds important information, since it is able to clarify
whether reappearing host cells are of leukemic origin or
are T cells or other nonmalignant cells.
In this article we have not focused specially on the use
of chimerism in the setting of dose-reduced conditioning,
since the detection of MRD is not substantially different
after this form of transplantation. However, since mixed
chimerism, especially in T cells, is much more common
after dose-reduced preparative regimens, subset analysis
is even more important to differentiate persistent mixed
T cell chimerism from reappearing leukemic cells.
Use of Chimerism for Follow-Up after
Transplantation: The Dresden Experience
Recently, several groups have published their proce-
dures for the follow-up investigations after allogeneic
HSCT [64–69]. These reports are mainly focused on tech-
nical issues. As discussed above these questions are cer-
tainly important. However, especially for the detection of
MRD, the use of the appropriate methods according to
the clinical situation is most important. Based on our own
experience and the literature data, our current recommen-
dations for chimerism analyses are as follows: During
engraftment and during the entire period of mixed macro-
chimerism (i.e. chimerism between 3 and 97%), STR
analysis, preferentially in a multiplex assay, should be
used on whole blood or bone marrow samples to quantify
chimerism. We usually perform these analyses twice
weekly starting at day +5. If graft failure or relapse is clini-
cally suspected, sorting of T cells, NK cells and myeloid
cells, preferentially CD34+ cells, might be helpful. Once
the chimerism in the peripheral blood has reached a level
of more than 97% donor, real-time PCR assays should be
used for further monitoring whenever possible. When
real-time PCR indicates that the level of residual host
cells further declines follow-up monitoring with real-time
PCR is recommended at regular intervals. When this
method indicates a level of residual host cells below
0.005%, the periods between the analyses may be in-
creased to 2–3 months, because up to now we have not
seen relapses when patients were at this low level. When
real-time PCR assays cannot be used, standard STR-PCR
should be performed at closer intervals. The length of the
intervals should be chosen according to the tendency of
relapse of the primary disease and the time after trans-
plantation, with more frequent analyses (weekly to every
2 weeks) performed in patients with high risk disease (like
AML or ALL) and early after transplantation. This very
tight schedule should be followed for the first 2 years after
transplantation, since the majority of relapses occur dur-
ing this period. If real-time PCR shows that the level of
host cells does not decline or increases again, subset analy-
sis (including T cells, CD15+ cells and, if possible, CD34+
cells) should be performed in order to clarify the origin of
these cells. Based on this information and the clinical situ-
ation (i.e. whether there is graft versus host disease
present or not and the individual relapse risk), reduction
of the immunosuppressive therapy or infusion of T cells
might be performed.
Thus in conclusion, we believe that chimerism analysis
can be performed for the detection of MRD, but the
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diverse methods currently available differ in their abili-
ties. If there is a genetic marker (translocation, IgVH rear-
rangement) which can be used for real-time PCR, this is
certainly the first choice for MRD detection, since these
markers are specific for leukemia. If not, chimerism anal-
ysis using the most sensitive and quantitative method
available should be used. We believe that a strategy like
this will allow for a more accurate and reliable assessment
of chimerism and might help to identify patients at risk of
a reappearance of leukemia. However, prospective trials
will clearly have to show whether these strategies can be
used to achieve a longer leukemia-free survival after
transplantation.
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